GlassScriptPhysician profile
John J Gould
NPI 1568424612
$4,811.83
in general payments reported to CMS, 2019-2025
34 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $351 · 2021: $446 · 2022: $924 · 2023: $1,069 · 2024: $757 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,353.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,074.76 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $687.98 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $525.23 | 2019-2024 | Xarelto |
| Amgen INC. | $314.40 | 2022-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $235.05 | 2019-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $189.12 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $189.03 | 2019-2023 | Brilinta |
| Pfizer INC. | $183.87 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $154.81 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $153.66 | 2019-2022 | |
| Amarin Pharma, INC. | $143.45 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.14 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.46 | 2022-2025 | Jardiance |
| Abbott Laboratories | $83.52 | 2023 | Amplatzer Amulet |
| Irhythm Technologies, INC. | $77.49 | 2022-2024 | Zio Xt Patch, Zio Monitor |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $66.28 | 2021-2025 | Ozempic |
| Lexicon Pharmaceuticals, INC. | $63.94 | 2023-2024 | Inpefa |
| Medtronic, INC. | $48.35 | 2022 | |
| Bridgebio Pharma, INC. | $48.12 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $42.21 | 2021 | |
| Philips North America LLC | $41.66 | 2020-2023 | |
| Scpharmaceuticals INC. | $38.33 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $37.88 | 2019 | |
| Alnylam Pharmaceuticals INC. | $36.29 | 2025 | Amvuttra |
| Portola Pharmaceuticals, LLC | $35.04 | 2019 | |
| Boston Scientific Corporation | $17.80 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $17.79 | 2023 | Arcalyst |
| Glaxosmithkline, LLC. | $14.86 | 2025 | Arexvy, Shingrix |
| Braemar Manufacturing, LLC | $13.65 | 2019 | |
| Elutia, INC. | $13.34 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.63 | 2020 | |
| Ge Healthcare | $12.11 | 2021 | |
| Astellas Pharma US INC | $11.58 | 2019 | |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gould listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.